ArticleJournal of thrombosis and haemostasis : JTH2022
Risk of venous thromboembolism after COVID-19 vaccination.
Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.JMIR public health and surveillance · 2025Pooled it
- Lessons Unlearned: The Barriers to Lyme Borreliosis Vaccination and the Risk of Repeating History.Vaccines · 2026Article
- Factors associated with thrombotic events among young adults in India, 2021-23: A multi-centric hospital-based matched case -control study.The Indian journal of medical research · 2026Article
- Venous Thrombosis Associated with Different Types of SARS-CoV-2 Vaccines in the Netherlands-Results of the TERA Case-Control Study.Thrombosis and haemostasis · 2026Article
- A comprehensive assessment of the impact of COVID variant and vaccination on venous thromboembolism and mortality.Research and practice in thrombosis and haemostasis · 2026Article
- Effectiveness and Safety of COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Retrospective Cohort Study.Korean circulation journal · 2026Article
- Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry.Internal and emergency medicine · 2025Article
- Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry.Internal and emergency medicine · 2025Article
- The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.The Korean journal of internal medicine · 2025Article
- Review
- Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer.ESMO real world data and digital oncology · 2025Article
- Review
- Article
- Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism.The Journal of infectious diseases · 2025Article
- COVID-19: a vascular nightmare unfolding.Frontiers in immunology · 2025Review
- The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications.Heart (British Cardiac Society) · 2024Article
- 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2024Review
- Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations.TH open : companion journal to thrombosis and haemostasis · 2023Article
- Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.Drug safety · 2023Article
- Epidemiology and prevention of venous thromboembolism.Nature reviews. Cardiology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 vaccinations in the United States are effective in preventing illness and hospitalization yet concern over post-vaccination venous thromboembolism (VTE) risk has led to vaccine hesitancy.
methodsThe aim of this study was to compare VTE rates before and after COVID-19 vaccination. COVID-19 vaccinated patients ≥18 years between November 1, 2020 through November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE (upper or lower deep vein thrombosis or pulmonary embolism) occurring 90 days before and after the date of first vaccine dose.
resultsA total of 792 010 patients with at least one COVID-19 vaccination were identified (Pfizer, n = 452 950, Moderna, n = 290 607, and Janssen [Johnson & Johnson], n = 48 453). A total of 1565 VTE events occurred in the 90 days before (n = 772) and after (n = 793) COVID-19 vaccination. VTE post-vaccination occurred in 326 patients receiving Moderna (0.11%, incidence rate [IR] 4.58 per 1000p-years), 425 patients receiving Pfizer (0.09%, IR 3.84 per 1000p-years), and 42 receiving Janssen (0.09%, IR 3.56 per 1000p-years). Compared to the pre-vaccination timeframe, the adjusted hazard ratio (aHR) for VTE after the Janssen vaccination was 0.97 (95% confidence interval [CI] 0.63-1.50), aHR 1.02 (95% CI 0.87-1.19) for Moderna, and aHR 1.00 (95% CI 0.87-1.15) for Pfizer.
conclusionIn this large cohort of COVID-19 vaccinated patients, no increased risk for acute VTE post-vaccination was identified for the authorized vaccines in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.